DEA Cannabis Rescheduling Process Hits Key Milestone

Procedural Milestone Moves Rescheduling Forward

The DEA rescheduling process hit a critical procedural checkpoint this week. The advancement continues the administrative review that began following the Department of Health and Human Services recommendation in August 2023. This milestone represents forward momentum in a process that's stretched across multiple administrations and faced repeated delays. While the DEA hasn't disclosed the specific nature of the procedural step, federal administrative law requires multiple stages of review before any controlled substance can be reclassified.

The rescheduling effort began in October 2022 when President Biden directed HHS and the Attorney General to review cannabis scheduling. HHS completed its scientific and medical evaluation in August 2023, recommending Schedule III placement. The DEA initiated its own review process shortly after, which includes notice-and-comment rulemaking under the Administrative Procedure Act.

For operators, the stakes are measured in billions. Schedule III classification would eliminate Internal Revenue Code Section 280E, which currently prohibits state-licensed cannabis businesses from deducting ordinary business expenses on federal tax returns. Multi-state operators report effective tax rates between 40% and 70% under the current regime.

What Schedule III Means for Operators and Patients

Rescheduling to Schedule III would preserve federal prohibition while unlocking significant tax relief for state-licensed businesses. Cannabis would remain a controlled substance, but operators could deduct rent, payroll, and operating expenses like any other business. Interstate commerce stays illegal. The conflict between state and federal law persists.

The operational impact is immediate: businesses paying 60% effective tax rates would drop to the mid-20s overnight, freeing capital for expansion and price competition.

For patients, the calculus is murkier. Schedule III drugs require a prescription, but the federal government doesn't recognize cannabis as medicine and FDA approval remains years away. State medical programs would continue operating under existing frameworks, but the rescheduling creates new legal ambiguity around prescription requirements versus state-issued medical cards.

Banking access would see limited improvement. The SAFE Banking Act remains stalled in Congress, and Schedule III doesn't remove cannabis from the Bank Secrecy Act's enhanced due diligence requirements. Financial institutions would still face regulatory uncertainty, though some regional banks may enter the market with rescheduling as political cover.

Timeline and Next Steps

The DEA must complete notice-and-comment rulemaking before finalizing any schedule change. That process typically spans 6 to 18 months from the notice of proposed rulemaking. The agency hasn't published an NPRM for cannabis rescheduling, meaning public comment and final rule publication remain ahead. Industry observers expect an NPRM before year-end 2026, with a final rule possible in 2027.

Political variables complicate the timeline. The 2026 midterm elections and the 2028 presidential race inject uncertainty into federal cannabis policy. A new administration could pause or reverse the rescheduling process, though HHS's scientific recommendation creates a high bar for reversal under administrative law.

For full background on the multi-year process, see the CannIntel topic hub on DEA cannabis rescheduling.

The cleanest read on timing: expect an NPRM by December 2026, public comment through Q1 2027, and a final rule by mid-2027 if the process proceeds without legal challenge. Litigation from prohibitionist groups or states is likely once the DEA publishes its proposed rule.